Pangea Biomed

Pangea Biomed is a precision oncology biotech company based in Tel Aviv, Israel, founded in 2018. The company focuses on RNA technology to enhance cancer care by integrating molecular biology, bioinformatics, and machine learning.

Pangea's main product is ENLIGHT, a proprietary computational platform that predicts individual responses to cancer treatments. This platform, developed from over a decade of research, includes two variants: ENLIGHT-NGS, which analyzes RNA sequencing data from tumor biopsies, and ENLIGHT-DP, which uses histopathology slide images. ENLIGHT identifies tumor vulnerabilities by examining gene interactions and various biological measures.

The company collaborates with pharmaceutical and biotech firms to optimize clinical trial designs and analyze drug mechanisms. Additionally, Pangea offers pro-bono treatment decision support for late-stage cancer patients in Israel, the US, and Europe who have exhausted standard treatment options. With a small team of fewer than 25 employees, Pangea has raised $12 million in funding to support its mission.